Moderna Shares Continue Slide Despite Regulatory Approval for Updated Vaccine
Published on 09/12/2025 at 15:09 | Redaktion boerse-global.deModerna’s stock remains under significant pressure despite achieving a critical regulatory milestone. The U.S. Food and Drug Administration recently granted approval for the company’s updated COVID-19 vaccine for the 2025-2026 season, yet this development has failed to reverse the persistent downward trend in its share price. Investors continue to offload positions, reflecting deep-seated concerns about the company’s post-pandemic trajectory.
The biotech firm, once celebrated as a pandemic hero, now confronts the harsh reality of a dramatically changed market landscape. A fundamental reassessment of vaccine manufacturers is underway, driven by evolving public health policies and adjusted vaccination recommendations across the globe. Moderna’s concentrated focus on mRNA technology leaves it particularly exposed to these sector-wide shifts.
The... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
